Nonpsychotropic Synthetic Cannabinoids

Author: Pop, E.

Source: Current Pharmaceutical Design, Volume 6, Number 13, 1 September 2000 , pp. 1347-1359(13)

Publisher: Bentham Science Publishers

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Unlike natural cannabinoids which belong to the 6aR - trans series, the synthetic dexanabinol (HU-211), a 6aS-trans enantiomer, does not have affinity toward cannabinoid receptors and is devoid of cannabimimetic activity. On the other hand, dexanabinol demonstrated significant neuroprotective properties which prompted its development as a therapeutic agent. We now present the extension of a series of 6aS-trans cannabinoids with novel derivatives, including water soluble derivatives and congeners of dexanabinol.

Keywords: Nonpsychotropic Synthetic Cannabinoids; 6aR - trans series; synthetic dexanabinol (HU-211); a 6aS-trans enantiomer; cannabimimetic activity; neuroprotective properties; therapeutic agent; 6aS-trans cannabinoids; Delta 9 tetrahydrocannabinol (THC); 6aS-trans enantiomeric series; noncompetitive N-methyl-D-aspartate (NMDA); tumor necrosis factor (TNF alpha); NMDA; Structures of dexanabinol (1) and HU-210 (2); DEXANABINOL; PM3; dexanabinol; Glycinate; substituted glycinate esters; Hetrocyclic nitrogen containing esters; Phenolic ester; Phosphate esters; Hemiesters; Pyridine 3 carboxylates; NMDA Receptor Binding; 6aS trans cannabinoids; Lactate dehydrogenase (LDH); NMDA Receptor binding properties; Novel 6aS trans cannabinoids; Gas or liquid chromatographic mass spectrometry (G